HK Stock Market Move | LENOVO GROUP(00992) rose more than 4%, the financial report for the first quarter of the fiscal year 2026 is about to be disclosed, the company's PC market share continues to increase.
Lenovo Group (00992) rose more than 4%, as of the time of writing, it was up 4.06% to 11.03 Hong Kong dollars, with a turnover of 1.137 billion Hong Kong dollars.
LENOVO GROUP (00992) rose more than 4%, up 4.06% as of press time, to HK$11.03, with a turnover of HK$1.137 billion.
On the news front, the board meeting of LENOVO GROUP will be held on August 13 (after trading hours) to review and approve (if applicable) the unaudited financial performance of the Group for the three months ended June 30, 2025. A report from Lyon Securities stated that after raising expectations on July 5, LENOVO GROUP's profit forecast for the April-June period has been further revised upwards. This is due to higher than expected shipment volume and profit margins in the Lenovo PC business, as well as strong revenue in the server business. Therefore, the target price of LENOVO GROUP has been raised from HK$11 to HK$12, with an outperform rating maintained.
J.P. Morgan pointed out that Lenovo's PC market share continues to increase, creating a virtuous cycle of income. According to Gartner data, Lenovo's PC shipments in April-June increased by 12% sequentially and 14% year-on-year. J.P. Morgan attributed this strong performance to higher than expected enterprise replacement demand and continuous market share gain from its US peers, pushing its global PC market share from 24.7% in the second quarter of 2024 to 26.9% in the second quarter of 2025. The larger scale may bring potential profit margin improvement in April-June due to stronger purchasing negotiation capabilities and better operational leverage.
Related Articles

Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) passed the drug cGMP on-site inspection.

BP p.l.c. Sponsored ADR (BP.US) exceeded earnings expectations in Q2. The new chairman will lead reforms and launch a comprehensive review of the business.

HK Stock Market Move | JUNSHI BIO (01877) rose nearly 35% in the final trading session. The company had previously raised over 1 billion for research and development of PD-1/VEGF bispecific antibodies, among other projects.
Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) passed the drug cGMP on-site inspection.

BP p.l.c. Sponsored ADR (BP.US) exceeded earnings expectations in Q2. The new chairman will lead reforms and launch a comprehensive review of the business.

HK Stock Market Move | JUNSHI BIO (01877) rose nearly 35% in the final trading session. The company had previously raised over 1 billion for research and development of PD-1/VEGF bispecific antibodies, among other projects.

RECOMMEND

EU Defers Two Retaliatory Measures Against U.S. Tariffs by Six Months to Facilitate Trade Negotiations
05/08/2025

July Special Bond Issuance Reaches Year-to-Date Peak, Poised to Reinforce Infrastructure Investment
05/08/2025

Inbound Tourism Accelerates as China’s Travel Service Exports Jump Nearly 70% in H1
05/08/2025